PYXS
Pyxis Oncology, Inc.Company with tickers: PYXS
CIK
1782223
CUSIP
747324101
Shares Outstanding
63,355,482
13F Activity (30d)
53 filings
52 filers
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
| Line Item | Value | Unit | Period End | Form | Filed |
|---|---|---|---|---|---|
| Revenue | — | ||||
| Revenue (ASC 606) | — | ||||
| Cost of Revenue | — | ||||
| Gross Profit | — | ||||
| Operating Expenses | $24,360,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Research & Development | $19,983,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Operating Income | $-24,360,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| Net Income | $-23,272,000 | USD | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Basic) | $-0.37 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |
| EPS (Diluted) | $-0.37 | USD/shares | 2026-03-31 | 10-Q | 2026-05-14 |